Strategic Brief · Privileged & Confidential
You are standing up Clarivate’s Life Sciences & Healthcare business — Cortellis and DRG — as an independent platform. Cortellis answers the molecule’s R&D questions. DRG answers its commercialization questions. HealthTech Alpha answers what your customers ask next: what the healthcare innovation ecosystem is doing around the molecule. This is not a better Cortellis. It is the layer Cortellis was never built to be — eleven years in the making, by Galen Growth.
Rather than describe HealthTech Alpha, we built a live, interactive demonstration of the decision workflow at its heart — so the Altaris team can put its hands on it before we ever get to a data room.
Choose a therapeutic area, a business objective, a region and a planning horizon — defending a franchise facing LOE, say, or mapping five years of obesity innovation — and watch the platform convert that question into an innovation landscape, priority opportunities, competitor intelligence, scenario analysis and an executive recommendation.
It is the fastest way to understand what LS&H’s ~2,500 accounts would be getting: not another database, but a decision engine — the enterprise workflow logic Cortellis and DRG customers already run, applied to the innovation ecosystem around the molecule.
Open the live demonstration →decision-workflow.galengrowth.com · every figure drawn from actual HealthTech Alpha data · variable set, weighting and scoring logic deliberately simplified for illustration
And when you are ready, the Galen Growth principals will run the combined graph live on one therapeutic area — HealthTech Alpha entities crosswalked to Cortellis pipeline and DRG market-access views, on your accounts’ own questions. Which digital-therapeutics products in type-2 diabetes have peer-reviewed adherence evidence — and which top-20 pharma do they partner with? Which CGM-adjacent ventures hold FDA clearance plus an active pharma co-development? Which technologies will shape market access for the next GLP-1 generation? The gap is the thesis — shown on a single screen.
Altaris is carving Clarivate’s Life Sciences & Healthcare business out for $600M — roughly 1.5× 2025 revenue on a ~$390M business — to run as an independent life-sciences intelligence platform, with close expected H2 2026. The roadmap you write between signing and close decides what that platform is on day one: a separation story, or a growth story. This page is about one decision on that roadmap.
The market priced LS&H the way it prices any scaled asset without a growth story. You bought the platform; what re-rates it is growth and workflow ownership. HealthTech Alpha is the growth layer that arrives complete — a new sellable coverage module, an entity-resolved crosswalk into Cortellis and DRG, and the evidence-graded data foundation the platform’s AI roadmap requires.
That is the read-across in one line: adjacency, not overlap. LS&H owns R&D, regulatory, epidemiology and market-access intelligence for the molecule; HealthTech Alpha extends the same intelligence stack into the 17,000+ ventures and products that pharma, medtech, payers, investors and providers now track as seriously as pipelines — and sells it to the same enterprise seats.
Galen Growth is the company behind HealthTech Alpha: a specialist intelligence platform for healthcare technology innovation. It is not a database to be re-keyed. It is the evidence-graded layer for the part of life sciences the LS&H platform doesn’t see — already structured, already scored, already in production with the same top-20 pharma on your platform.
Much of the underlying source material is public; that is precisely the point. HealthTech Alpha’s value is how it collects, structures, normalises and indexes fragmented healthcare-innovation information into decision-grade intelligence: a healthcare-native ontology rather than keyword search; a venture-product-evidence graph connecting companies to products, trials, approvals, customers and partnerships; longitudinal global coverage; and proprietary signals — Alpha Score, Evidence Signal, Partnership Signal, Team Signal, Product Score — that raw access to the same sources cannot reproduce.
Nothing in the module competes with a Cortellis or DRG product line, so the addition is clean to execute even inside a carve-out. And as AI becomes the interface, generic answers are not enough — the data layer itself has to be curated, indexed and auditable, which is exactly what a raw LLM cannot provide. Evidence grading and codified expert judgement are precisely that infrastructure: a workflow and a customer base built over eleven years, not a feature to ship.
Every serious acquirer of this asset asks the same five questions. Here are the answers, plainly.
With a patchwork: generalist databases that are funding-first and weak on healthcare evidence and product depth; Google and manual research that is slow and hard to reproduce; internal spreadsheets that fragment and date quickly; consultants who are point-in-time; expert networks that don’t scale — and, increasingly, general-purpose LLMs that are plausible but ungrounded, with no provenance and no audit trail.
The moment a team must move from a broad market question to something defensible: a shortlist, a competitor map, a portfolio view, a partner universe, a board-ready decision. That is where the patchwork breaks and HTA becomes compelling.
Not raw access — conversion. The healthcare-native ontology, the venture-product-evidence graph, the longitudinal coverage and the proprietary scoring turn public fragments into decision-grade intelligence. The live demonstration shows the result in practice.
Adopted across pharma, medtech, health insurers, health systems, investors and advisors — large pharma, medical-device firms, insurers, public-health bodies and consultancies among them — on repeatable use cases: ecosystem mapping, competitor benchmarking, partner scouting, portfolio evaluation and market intelligence. The product has evolved from database to intelligence platform: Alpha Copilot, Alpha Edge, scoring, signals and enterprise access. Shown here at a strategic level; diligence detail follows the fit discussion.
Adjacency, not overlap. LS&H owns the molecule’s lifecycle intelligence; HTA extends the same stack into the innovation around it — digital health, AI-enabled care models, clinical-trial innovation, patient support, evidence generation, and partnership and commercialisation pathways — shipped as a module through the commercial engine you already run, into ~2,500 accounts, plus buyer types the platform doesn’t yet serve at scale: investors, payers, providers, consultancies.
The fastest check on all five is the live decision-workflow demonstration — a strategic question in, an evidence-based recommendation out, on actual HealthTech Alpha data. Open the demo →
Put the engine inside the platform you just bought — don’t bolt a layer onto the side of it.
HealthTech Alpha’s ontology joins its companies, products, partnerships, trials and regulatory records to Cortellis pipeline entities and DRG market-access data — one resolved graph from molecule to innovation ecosystem.
Healthcare-technology innovation intelligence ships as a module in the commercial engine you already run — an upsell to ~2,500 accounts, plus buyer types the platform doesn’t yet serve at scale: investors, payers, providers, consultancies.
AI-enabled intelligence workflows need curated, auditable domain data. Evidence grading is precisely that infrastructure — a workflow and a customer base built over eleven years, not a feature to ship.
HTA supports the decision workflow around the molecule: where to partner, where to acquire, where to monitor, and where competitors are already moving — scan → shortlist → compare → evaluate → monitor, as the demonstration shows live.
Illustrative, deliberately conservative, and yours to replace. Three levers decide what the module is worth to the platform.
A build cannot close this gap on a carve-out timeline — and the window to shape the day-one roadmap is between signing and close.
“Bolted into Cortellis and DRG, HealthTech Alpha is immediately accretive — and strategically decisive: it extends the platform from the molecule lifecycle to the innovation ecosystem its customers increasingly pay to understand.”
Galen Growth has been deliberate about where eleven years of curation lands. The right home is the platform where healthcare-technology intelligence becomes core infrastructure for the industry — not a feature inside someone else’s product. A focused, independent LS&H, resourced by a healthcare-exclusive owner, is that home. The principals seek an outright sale, are flexible on structure and timing — including alignment to your close calendar — and intend to lead the layer inside the platform.
The strategic process is being run by Kane & Company, retained sell-side advisor to Galen Growth. Principal participation is available once a mutual NDA is in place.
Thirty minutes where the Galen Growth principals show the combined graph on one therapeutic area — HealthTech Alpha crosswalked to Cortellis and DRG views, on your accounts’ own questions. The live decision-workflow demonstration is open now, and the full brief is available on request.